Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael Kenneth Keng
Michael Kenneth Keng
University of Virginia Health System
Medicine
Oncology
Internal medicine
Myeloid leukemia
high dose cytarabine
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
2021
Journal of Clinical Oncology
Sharif S. Khan
Shahram Mori
Deepa Jeyakumar
Michael Kenneth Keng
Hemant S. Murthy
Michal Bar-Natan
Krishna Gundabolu
Kristen M. ODwyer
Tulio E. Rodriguez
Anthony S. Stein
Wendy Stock
Caspian Oliai
Christopher McCann
Faraz Zaman
Gerhard Zugmaier
Paul Gordon
Timothy S. Pardee
Show All
Source
Cite
Save
Citations (0)
Minimizing the risk of Clostridium difficile infection as an early complication of autologous stem cell transplantation.
2021
Journal of Clinical Oncology
Joseph Van Galen
Samuel Maldonado
Leonid Volodin
Michael Kenneth Keng
Show All
Source
Cite
Save
Citations (0)
Reducing length of stay for patients with acute myeloid leukemia receiving inpatient high-dose cytarabine consolidation chemotherapy.
2021
Journal of Clinical Oncology
Caroline Jones
David O. Riley
Amy Morris
Jeremy Sen
Alana Ferrari
Joshua Humphrey
Jenna VanHoose
Nicholas Schmidt
Jenna Schlefman
Firas El El Chaer
Michael Kenneth Keng
Show All
Source
Cite
Save
Citations (0)
1